Alexander Teague
Papers
2
Total Citations
145
H-Index
2
About
Alexander Teague is pioneering the use of living organisms as personalized drug-testing platforms for rare and difficult-to-treat cancers. His key research integrates functional genomics, robotics, and developmental biology to create patient-specific models using *Drosophila* (fruit flies) and hindgut organoids. In his most cited work (107 citations), Teague developed a robotics-based screening platform that identified the combination of trametinib and zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. This personalized approach yielded a striking clinical response, with target and nontarget lesions showing a strong partial response that remained stable for 11 months. Expanding this concept, his 2021 study (38 citations) demonstrated the first use of a *Drosophila* platform to identify a novel therapy for adenoid cystic carcinoma, a rare salivary gland cancer with limited treatment options. By bridging bench-to-bedside medicine with high-throughput in vivo modeling, Teague is redefining precision oncology—offering new hope for patients with aggressive, therapy-resistant malignancies where conventional approaches have failed.
Research Focus
Key Achievements
Top Papers
- 1
- 2